Biologics & Biosimilars, Monoclonal Antibody

Xentria is a biotech company focused on developing innovative drug therapies, particularly for rare diseases such as pulmonary sarcoidosis. Their lead candidate, XTMAB-16, is a monoclonal antibody designed to inhibit tumor necrosis factor alpha (TNFα), a key regulator of inflammation that contributes to the formation of granulomas in sarcoidosis patients. The company emphasizes a collaborative approach, engaging with experts, patients, and healthcare providers to inform their drug development process. This patient-centered strategy aims to address the significant unmet needs in sarcoidosis treatment, where existing therapies do not modify the disease's progression.

The development of XTMAB-16 is characterized by a data-driven methodology that incorporates insights from non-clinical testing and patient advocacy. Xentria has established a framework for risk assessment and has actively sought input from key opinion leaders to shape their clinical trial design. They have also received FDA Orphan Drug Designation for XTMAB-16, highlighting their commitment to navigating the complexities of rare disease drug development. Through these efforts, Xentria aims to create a robust clinical development program that not only focuses on the safety and efficacy of their investigational drug but also fosters strong partnerships within the life sciences community to enhance patient outcomes.

United States

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families.  Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership.  We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.

Xentria

Company Details